Koshorek Jacqueline, Wang Yujie, Maldonado Daniela Pimentel, Reyes-Mantilla Maria I, Obando Danielle, Balshi Alexandra, Comisac Michael, Pasricha Pankaj Jay, Newsome Scott D
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Neurology, University of Washington School of Medicine, Seattle, WA, United States.
Front Neurol. 2023 Oct 6;14:1273256. doi: 10.3389/fneur.2023.1273256. eCollection 2023.
The effect of stiff person syndrome spectrum disorders (SPSD) on the gastrointestinal tract (GIT) is unknown. This case series aims to characterize the prevalence and types of GI dysfunction in individuals with SPSD.
A retrospective chart review included individuals diagnosed with SPSD with descriptors of GI symptoms in their medical records. SPSD phenotypes, type of motility test performed, and dysmotility pattern (upper, lower, or diffuse) were assessed. Descriptive statistics and univariate chi-square analyses were utilized.
Of 240 individuals with SPSD, 32% reported GI symptoms, most were female (83.1%), and white (74%), with a median age at time of GI symptom onset of 50 ± 13 years. Most common symptoms reported were dysphagia (45%), constipation (40%), and nausea/vomiting (23%). Most individuals had classic SPS (47%) followed by SPS-plus (29%) and 82.9% were positive for serum antiGAD65 antibodies. Of 36 patients that underwent at least one GI motility test, 26 had evidence of upper, lower, or diffuse GI dysmotility (44.4%, 17%, and 4%, respectively). The group who did not undergo testing had a higher proportion of patients with DM.
There is a high prevalence of GI symptoms and transit abnormalities in patients with SPSD. Future prospective, longitudinal studies are warranted to further assess GI symptoms in the context of SPSD and to determine if individuals with GI symptoms differ in prognosis or treatment response from those without GI symptoms. In the meantime, there should be a low threshold for motility testing in patients with SPSD.
僵人综合征谱系障碍(SPSD)对胃肠道(GIT)的影响尚不清楚。本病例系列旨在描述SPSD患者胃肠道功能障碍的患病率和类型。
一项回顾性病历审查纳入了诊断为SPSD且病历中有胃肠道症状描述的个体。评估了SPSD表型、进行的动力测试类型以及动力障碍模式(上消化道、下消化道或弥漫性)。采用描述性统计和单变量卡方分析。
在240例SPSD患者中,32%报告有胃肠道症状,大多数为女性(83.1%),白人(74%),胃肠道症状出现时的中位年龄为50±13岁。报告的最常见症状为吞咽困难(45%)、便秘(40%)和恶心/呕吐(23%)。大多数个体患有经典型SPS(47%),其次是SPS加型(29%),82.9%的患者血清抗GAD65抗体呈阳性。在36例至少进行过一次胃肠道动力测试的患者中,26例有上消化道、下消化道或弥漫性胃肠道动力障碍的证据(分别为44.4%、17%和4%)。未进行测试的组中糖尿病患者比例更高。
SPSD患者中胃肠道症状和转运异常的患病率较高。未来有必要进行前瞻性纵向研究,以在SPSD背景下进一步评估胃肠道症状,并确定有胃肠道症状的个体与无胃肠道症状的个体在预后或治疗反应方面是否存在差异。同时,对于SPSD患者,动力测试的阈值应较低。